PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11675331-7	2001	Furthermore, the risk of partial or no response to fludarabine increased with increasing CD38 expression (P =.003), and a shorter overall survival (50% versus 92% at 8 years; P <.00001) characterized patients with more than 30% CD38(+) B-cell number.	fludarabine	51-62	CD38 molecule	Homo sapiens	89-93	
10477712-5	1999	Patients in both the unmutated and the >/=30% CD38(+) groups responded poorly to continuous multiregimen chemotherapy (including fludarabine) and had shorter survival.	fludarabine	132-143	CD38 molecule	Homo sapiens	49-53	
32231196-16	2020	CONCLUSION: Expression status of the CD5, CD20, CD37, CD38, CD40, CD150, and CD180 cell surface receptors could be used in prediction CLL B cells sensitivity to FLU, CP, BEN and FC ex vivo.	fludarabine	161-164	CD38 molecule	Homo sapiens	54-58	
31024917-14	2019	18F-fludarabine and immuno-PET targeting CD138 and CD38 also showed promising results in preclinical models.	fludarabine	4-15	CD38 molecule	Homo sapiens	51-55	
16404355-5	2005	The significance of CD38 expression for CLL prognosis was revealed as predictor for response for fludarabine treatment and time of progression in advanced stages.	fludarabine	97-108	CD38 molecule	Homo sapiens	20-24